BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35460832)

  • 21. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its Partners to Overcome Metastasis and Drug Resistance.
    Butt G; Shahwar D; Qureshi MZ; Attar R; Akram M; Birinci Y; Karatoprak GS; Gasparri ML; Farooqi AA
    Adv Exp Med Biol; 2019; 1152():283-292. PubMed ID: 31456190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic Target of Rapamycin Is a Novel Molecular Mechanism Linking Folate Availability and Cell Function.
    Silva E; Rosario FJ; Powell TL; Jansson T
    J Nutr; 2017 Jul; 147(7):1237-1242. PubMed ID: 28592519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer.
    Chen Y; Qian J; He Q; Zhao H; Toral-Barza L; Shi C; Zhang X; Wu J; Yu K
    Oncotarget; 2016 May; 7(18):25224-40. PubMed ID: 27015560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR links oncogenic signaling to tumor cell metabolism.
    Yecies JL; Manning BD
    J Mol Med (Berl); 2011 Mar; 89(3):221-8. PubMed ID: 21301797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical interaction of estrogen receptor with MnSOD: implication in mitochondrial O
    Lone MU; Baghel KS; Kanchan RK; Shrivastava R; Malik SA; Tewari BN; Tripathi C; Negi MP; Garg VK; Sharma M; Bhatt ML; Bhadauria S
    Oncogene; 2017 Mar; 36(13):1829-1839. PubMed ID: 27721400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription via the mTORC1/NF-κB Signaling Pathways.
    Zhang J; Jia L; Lin W; Yip YL; Lo KW; Lau VMY; Zhu D; Tsang CM; Zhou Y; Deng W; Lung HL; Lung ML; Cheung LM; Tsao SW
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28053105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial proteomic analysis of human host cells infected with H3N2 swine influenza virus.
    Wu X; Wang H; Bai L; Yu Y; Sun Z; Yan Y; Zhou J
    J Proteomics; 2013 Oct; 91():136-50. PubMed ID: 23856606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress.
    Lin A; Yao J; Zhuang L; Wang D; Han J; Lam EW; Gan B
    Oncogene; 2014 Jun; 33(24):3183-94. PubMed ID: 23851496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
    Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
    Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression.
    Chen Z; Zhang Y; Jia C; Wang Y; Lai P; Zhou X; Wang Y; Song Q; Lin J; Ren Z; Gao Q; Zhao Z; Zheng H; Wan Z; Gao T; Zhao A; Dai Y; Bai X
    Oncogene; 2014 Sep; 33(37):4548-57. PubMed ID: 24096482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
    Sharma A; Janocha AJ; Hill BT; Smith MR; Erzurum SC; Almasan A
    Mol Cancer Res; 2014 Sep; 12(9):1205-15. PubMed ID: 25061101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.
    Lu W; Lin C; Li Y
    Cell Signal; 2014 Jun; 26(6):1303-9. PubMed ID: 24607787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
    Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
    J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
    Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
    Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
    PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.